Please login to the form below
Cellectis
This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka
The latest from pharma, biotech and healthcare. Cellectis gains senior scientist from Novartis. ... on the development and long-term strategic planning for Cellectis’ innovative product portfolio,” said Dr.
Latest news
-
Sangamo bulks up in cell therapy with TxCell acquisition
Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured TALENS.
-
Gilead signs $3bn-plus gene-editing deal with Sangamo
The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’ favoured
-
Cellectis floored by patient death in CAR-T trial
It may be that the FDA will exercise greater caution in Cellectis' case. ... UCART19 is partnered with Servier and Pfizer. Cellectis' Nasdaq-listed shares are currently trading at around $25, down from more than $32 ahead of the patient death announcement
-
Servier cleared to start US trials CAR-T therapy
The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’ CAR-T
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
Cellectis has been given the go-ahead by the FDA to start trials of its CAR-T immunotherapy UCART123 in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients however.
More from news
Approximately 8 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
2019: CRISPR and therapeutic gene editing comes of age
Companies like Cellectis and partner Allogene are deploying TALEN to take a slightly different approach, using the gene-editing tool to create ‘off-the-shelf’ CAR-Ts that don’t require ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers
-
Cutting through the noise: CRISPR
Cell therapy company Cellectis remains an exponent of TALEN, while Bluebird is using a next- generation platform called MegaTals.
-
Deal Watch November 2015
379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
-
Pharma deals in May 2015
Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.
-
Pharma deals in March 2015
Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.
-
Cellectis’ Mathieu Simon will serve as interim chief medical officer
He will take over the responsibilities of Loan Hoang-Sayag. Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag, who has ... As current executive vice president and chief operating officer,
-
Rainer Boehm and Hervé Hoppenot join Cellectics board
I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. ... I am excited to be joining the Cellectis board during this important time of growth.”.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Meanwhile, Pierre Schwich (pictured left) joins Pharnext from Cellectis where he served as chief financial officer from 2011 until 2014. ... Before joining Cellectis, he served as chief financial officer and corporate secretary for Genesys Conferencing,
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- GSK hires Merck KGaA exec to lead US pharma business
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- Novartis chooses internal replacement for US pharma president role
PMHub
Makara Health
Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
